Molecular alterations underlying epileptogenesis after prolonged febrile seizure and modulation by erythropoietin

Keun-Hwa Jung1, Kon Chu, Soon-Tae Lee

  • 1Stroke & Stem Cell Laboratory in Clinical Research Institute, Stem Cell Research Center, Department of Neurology, Seoul National University, Seoul, South Korea.

Epilepsia
|January 29, 2011
PubMed

Insights

Erythropoietin (EPO) treatment may prevent epilepsy after complex febrile seizures by reducing brain inflammation and molecular changes. This intervention targets key pathways identified in a rat model, offering a potential new strategy for susceptible individuals.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Epilepsy Research

Background:

  • Complex febrile seizures increase epilepsy risk in children.
  • Identifying molecular targets in animal models is crucial for developing interventions.
  • A latent period exists between febrile seizures and epilepsy development.

Purpose of the Study:

  • To investigate molecular changes in the rat brain during the latent period following febrile seizures.
  • To evaluate erythropoietin (EPO) as a potential antiepileptogenic intervention.

Main Methods:

  • Gene expression patterns (continuously high, continuously low, rise and fall, going-up) were analyzed during the latent period.
  • Erythropoietin was administered to rats post-seizure.
  • Spontaneous recurrent seizures, cellular, and molecular changes were monitored.

Main Results:

  • Gene expression changes were linked to cell cycle, metabolism, inflammation, apoptosis, GABA signaling, ion transport, and synaptogenesis.
  • Early latent period showed increased inflammatory genes, brain edema, and activated microglia.
  • Erythropoietin reduced early inflammation and modulated molecular alterations, decreasing subsequent seizure risk.

Conclusions:

  • Erythropoietin treatment shows promise in preventing epilepsy after atypical febrile seizures.
  • This highlights a potential novel therapeutic strategy for epilepsy prevention.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures l: Introduction01:20

Seizures l: Introduction

Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...